Altimmune, Inc.ALTNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank93
5Y CAGR+223.3%
Studio
Year-over-Year Change

Enterprise value to sales ratio

5Y CAGR
+223.3%/yr
Long-term compound
Percentile
P93
Near historical high
vs 5Y Ago
353.4x
Strong expansion
Streak
1 yr
Consecutive declineElevated
PeriodValueYoY Change
20257560.58-68.3%
202423834.48+2085.5%
20231090.57+111.2%
2022-9734.79-22767.6%
202142.95+100.8%
202021.39+605.6%
20193.03+214.4%
2018-2.65-100.7%
2017403.88+1826.9%
2016-23.39-